Andres Redondo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5868718/publications.pdf

Version: 2024-02-01

138 papers	7,763 citations	230014 27 h-index	62345 84 g-index
145 all docs	145 docs citations	145 times ranked	10535 citing authors

#	Article	IF	Citations
1	Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer. Modern Pathology, 2022, 35, 256-265.	2.9	12
2	Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. Gynecologic Oncology, 2022, 164, 406-414.	0.6	4
3	Dostarlimab for the treatment of advanced endometrial cancer. Expert Review of Clinical Pharmacology, 2022, 15, 1-9.	1.3	14
4	Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers, 2022, 14, 915.	1.7	4
5	Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. Cancers, 2022, 14, 912.	1.7	4
6	Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models. Frontiers in Oncology, 2022, 12, 862321.	1.3	1
7	Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?. Clinical and Translational Oncology, 2021, 23, 536-542.	1.2	5
8	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clinical and Translational Oncology, 2021, 23, 1245-1252.	1.2	21
9	SEOM clinical guideline in ovarian cancer (2020). Clinical and Translational Oncology, 2021, 23, 961-968.	1.2	22
10	Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling. Cancers, 2021, 13, 794.	1.7	31
11	Inflammatory indexes neutrophils/lymphocytes, platelets/lymphocytes and red-cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumors (SFT) treated with pazopanib: Correlative study of GEIS-32 trial.. Journal of Clinical Oncology, 2021, 39, 11511-11511.	0.8	0
12	A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.. Journal of Clinical Oncology, 2021, 39, 11534-11534.	0.8	1
13	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 609-619.	5.1	186
14	Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Journal of Ovarian Research, 2021, 14, 72.	1.3	2
15	Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.. Journal of Clinical Oncology, 2021, 39, 11564-11564.	0.8	4
16	GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).. Journal of Clinical Oncology, 2021, 39, 11529-11529.	0.8	1
17	Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).. Journal of Clinical Oncology, 2021, 39, 5549-5549.	0.8	1
18	Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phaseÂII trial (ROLANDO study). ESMO Open, 2021, 6, 100212.	2.0	15

#	Article	IF	Citations
19	Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1167-1176.	1.4	26
20	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS â€“ GROUP). Part I. Cancer Treatment Reviews, 2021, 99, 102259.	3.4	6
21	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS â€“GROUP). Part II. Cancer Treatment Reviews, 2021, 99, 102260.	3.4	7
22	Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases. International Journal of Gynecological Cancer, 2021, 31, 1292-1296.	1.2	2
23	Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?. Cancer Cell International, 2021, 21, 646.	1.8	6
24	The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. European Journal of Cancer, Supplement, 2020, 15, 49-55.	2.2	9
25	Are antiangiogenics a good â€˜partnerâ€™ for immunotherapy in ovarian cancer?. Angiogenesis, 2020, 23, 543-557.	3.7	10
26	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85
27	Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecologic Oncology, 2020, 159, 142-149.	0.6	30
28	Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. Clinical and Translational Oncology, 2020, 22, 1849-1856.	1.2	12
29	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer â€“ a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). International Journal of Gynecological Cancer, 2020, 30, 1997-2001.	1.2	11
30	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. JAMA Oncology, 2020, 6, 535.	3.4	33
31	Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. Obstetrical and Gynecological Survey, 2020, 75, 29-31.	0.2	2
32	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 456-466.	5.1	51
33	SEOM clinical guidelines for cervical cancer (2019). Clinical and Translational Oncology, 2020, 22, 270-278.	1.2	13
34	Patientâ€reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2â€“positive breast cancer. Cancer, 2020, 126, 3132-3139.	2.0	14
35	Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcomaâ€”A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.. Journal of Clinical Oncology, 2020, 38, 11514-11514.	0.8	7
36	IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.. Journal of Clinical Oncology, 2020, 38, 11522-11522.	0.8	14

#	Article	IF	Citations
37	Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.. Journal of Clinical Oncology, 2020, 38, e18032-e18032.	0.8	2
38	3D Culture Modelling: An Emerging Approach for Translational Cancer Research in Sarcomas. Current Medicinal Chemistry, 2020, 27, 4778-4788.	1.2	6
39	Patient-reported outcomes (PRO) in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab in the GARNET trial.. Journal of Clinical Oncology, 2020, 38, 275-275.	0.8	2
40	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1252-1262.	5.1	57
41	Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC). Annals of Oncology, 2019, 30, v429.	0.6	3
42	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2391-2402.	13.9	1,337
43	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 1141-1147.	1.2	11
44	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2019, 20, 862-876.	5.1	68
45	Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. Cancers, 2019, 11, 1845.	1.7	17
46	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 134-144.	5.1	97
47	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 2019, 380, 617-628.	13.9	1,610
48	Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.. Journal of Clinical Oncology, 2019, 37, 513-513.	0.8	3
49	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2019, 37, TPS5601-TPS5601.	0.8	3
50	Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.. Journal of Clinical Oncology, 2019, 37, 11038-11038.	0.8	0
51	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Targeted Oncology, 2018, 13, 81-87.	1.7	8
52	SEOM clinical guidelines for endometrial cancer (2017). Clinical and Translational Oncology, 2018, 20, 29-37.	1.2	27
53	Assessment of socio-economic, physical and mental health status of long-term cancer survivors. Annals of Oncology, 2018, 29, viii624-viii625.	0.6	0
54	Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. OncoTargets and Therapy, 2018, Volume 11, 5845-5852.	1.0	6

#	Article	IF	Citations
55	Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes. Anticancer Research, 2018, 38, 5393-5400.	0.5	11
56	Safety and dose modification for patients receiving niraparib. Annals of Oncology, 2018, 29, 1784-1792.	0.6	125
57	The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance. Scientific Reports, 2018, 8, 8485.	1.6	26
58	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research, 2018, 24, 5239-5249.	3.2	21
59	IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypesâ€"Results of the phase I part.. Journal of Clinical Oncology, 2018, 36, 11515-11515.	0.8	8
60	Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.. Journal of Clinical Oncology, 2018, 36, 11542-11542.	0.8	2
61	Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).. Journal of Clinical Oncology, 2018, 36, 5528-5528.	0.8	3
62	High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. Oncotarget, 2018, 9, 21893-21903.	0.8	21
63	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Annals of Oncology, 2017, 28, 711-717.	0.6	125
64	Malignant bone tumors (other than Ewingâ€™s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemotherapy and Pharmacology, 2017, 80, 1113-1131.	1.1	30
65	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals of Oncology, 2017, 28, 2994-2999.	0.6	45
66	A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology, 2017, 19, 616-624.	1.2	3
67	Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2017, 23, 1227-1235.	3.2	16
68	Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.. Journal of Clinical Oncology, 2017, 35, 11003-11003.	0.8	3
69	International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.. Journal of Clinical Oncology, 2017, 35, 11062-11062.	0.8	3
70	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.. Journal of Clinical Oncology, 2017, 35, 5577-5577.	0.8	1
71	Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer. PLoS ONE, 2017, 12, e0183452.	1.1	11
72	CD8+ TILs in early stage epithelial ovarian cancer: A GEICO study.. Journal of Clinical Oncology, 2017, 35, 5543-5543.	0.8	0

#	Article	IF	Citations
73	Long-term cancer survivors: Satisfaction with medical care and information received during the diagnosis and treatment of cancer.. Journal of Clinical Oncology, 2017, 35, e21573-e21573.	0.8	0
74	Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA.. Journal of Clinical Oncology, 2017, 35, e12563-e12563.	0.8	0
75	The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. Journal of Gynecologic Oncology, 2016, 27, e7.	1.0	30
76	SEOM Clinical Guideline in ovarian cancer (2016). Clinical and Translational Oncology, 2016, 18, 1206-1212.	1.2	15
77	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. Journal of Clinical Oncology, 2016, 34, 2294-2302.	0.8	61
78	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine, 2016, 375, 2154-2164.	13.9	1,860
79	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecologic Oncology, 2016, 143, 27-34.	0.6	81
80	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clinical Sarcoma Research, 2016, 6, 10.	2.3	1
81	CUL4A and ERCC1 genesas predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study.. Journal of Clinical Oncology, 2016, 34, 11048-11048.	0.8	2
82	CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2016, 34, TPS5597-TPS5597.	0.8	6
83	Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. Oncotarget, 2016, 7, 24217-24227.	0.8	8
84	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.. Journal of Clinical Oncology, 2016, 34, TPS2598-TPS2598.	0.8	0
85	Prolonged Response to Aflibercept in Ovarian Cancer Relapse: A Case Report. Tumori, 2015, 101, e29-e31.	0.6	3
86	SEOM guidelines for cervical cancer. Clinical and Translational Oncology, 2015, 17, 1036-1042.	1.2	27
87	Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). Annals of Surgical Oncology, 2015, 22, 2948-2957.	0.7	47
88	Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.. Journal of Clinical Oncology, 2015, 33, 10530-10530.	0.8	1
89	Long-term functional results and quality of life after open partial laryngectomy and non-surgical larynx preservation.. Journal of Clinical Oncology, 2015, 33, e17056-e17056.	0.8	0
90	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II studyâ€"GETHI 2013-01.. Journal of Clinical Oncology, 2015, 33, TPS5612-TPS5612.	0.8	1

#	Article	IF	Citations
91	Neutrophil-lymphocite ratio in stage II-III testicular germ cell tumors before initiating chemotherapy: Correlation with survival.. Journal of Clinical Oncology, 2015, 33, e15564-e15564.	0.8	0
92	Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry.. Journal of Clinical Oncology, 2015, 33, 5554-5554.	0.8	1
93	Predictive factors of early death after a comprehensive geriatric assessment in elderly cancer patients.. Journal of Clinical Oncology, 2015, 33, e20530-e20530.	0.8	0
94	Predictive factors of grade 3-5 toxicity in elderly cancer patients treated with chemotherapy: A prospective multicenter study (TEP study: Toxicity in Elderly Patient).. Journal of Clinical Oncology, 2015, 33, e20535-e20535.	0.8	0
95	Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer. OncoTargets and Therapy, 2014, 7, 2175.	1.0	11
96	NIS Mediates Iodide Uptake in the Female Reproductive Tract and Is a Poor Prognostic Factor in Ovarian Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1199-E1208.	1.8	26
97	SEOM guideline in ovarian cancer 2014. Clinical and Translational Oncology, 2014, 16, 1067-1071.	1.2	13
98	Anti-Angiopoietin Therapy With Trebananib for Recurrent Ovarian Cancer (TRINOVA-1). Obstetrical and Gynecological Survey, 2014, 69, 661-662.	0.2	1
99	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 799-808.	5.1	279
100	Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicinâ€"A GEIS study.. Journal of Clinical Oncology, 2014, 32, 10500-10500.	0.8	2
101	Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.. Journal of Clinical Oncology, 2014, 32, 10594-10594.	0.8	2
102	Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer (MBC) treated with bevacizumab and weekly paclitaxel (Bev-Pac).. Journal of Clinical Oncology, 2014, 32, 564-564.	0.8	2
103	Nilotinib as co-adjuvant treatment with doxorubicin in sarcomas: Phase I trial resultsâ€"A Spanish Group for Research on Sarcoma (GEIS) study.. Journal of Clinical Oncology, 2014, 32, 10573-10573.	0.8	0
104	Head and neck cancer in the elderly: Survival and toxicity with biochemoradiation therapy.. Journal of Clinical Oncology, 2014, 32, e17054-e17054.	0.8	0
105	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.. Journal of Clinical Oncology, 2014, 32, TPS5626-TPS5626.	0.8	0
106	Early-stage ovarian cancer: Clinical outcome and analysis of prognostic factorsâ€"Results from a prospective registry of GEICO (Spanish Group for Ovarian Cancer Research).. Journal of Clinical Oncology, 2014, 32, 5582-5582.	0.8	0
107	Expression of angiopoietin (Ang) pathway markers and their relationship to progression-free survival (PFS) in TRINOVA-1.. Journal of Clinical Oncology, 2014, 32, 5542-5542.	0.8	0
108	Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03).. Journal of Clinical Oncology, 2014, 32, 5558-5558.	0.8	0

#	Article	IF	Citations
109	SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013. Clinical and Translational Oncology, 2013, 15, 1037-1043.	1.2	11
110	GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clinical and Translational Oncology, 2013, 15, 509-525.	1.2	9
111	Efficacy and safety of front-line bevacizumab (BEV), weekly paclitaxel (wPAC), and q3w carboplatin (C) in elderly patients (pts) with ovarian cancer (OC): Subgroup analysis of OCTAVIA.. Journal of Clinical Oncology, 2013, 31, 5544-5544.	0.8	2
112	Long-term responders to first-line bevacizumab-based therapy among patients (pts) with HER2-negative metastatic breast cancer (MBC): Retrospective results of an ambispective observational study.. Journal of Clinical Oncology, 2013, 31, e12558-e12558.	0.8	0
113	mTOR pathway inhibition in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 356-361.	0.8	8
114	Targeting the endothelin axis in prostate carcinoma. Tumor Biology, 2012, 33, 421-426.	0.8	29
115	Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.. Journal of Clinical Oncology, 2012, 30, 10052-10052.	0.8	3
116	Gene profiling in breast cancer: Time to move forward. Cancer Treatment Reviews, 2011, 37, 416-21.	3.4	8
117	Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients. International Journal of Gynecological Cancer, 2011, 21, 1048-1055.	1.2	11
118	From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer. Expert Opinion on Investigational Drugs, 2011, 20, 591-594.	1.9	3
119	Angiogenesis as a therapeutic target in urothelial carcinoma. Anti-Cancer Drugs, 2010, 21, 890-896.	0.7	20
120	An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer. BMC Cancer, 2010, 10, 336.	1.1	22
121	Molecular characterization of ovarian cancer by gene-expression profiling. Gynecologic Oncology, 2010, 118, 88-92.	0.6	41
122	The miR-200 family controls Â-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocrine-Related Cancer, 2010, 18, 85-95.	1.6	188
123	Angiogenesis and ovarian cancer. Clinical and Translational Oncology, 2009, 11, 564-571.	1.2	59
124	Intra-abdominal desmoplastic small round cell tumour in a 39-year-old man. Clinical and Translational Oncology, 2009, 11, 770-772.	1.2	0
125	Aurora kinases as prognostic biomarkers in ovarian carcinoma. Human Pathology, 2009, 40, 631-638.	1.1	35
126	Comparison of Prognostic Gene Profiles Using qRT-PCR in Paraffin Samples: A Retrospective Study in Patients with Early Breast Cancer. PLoS ONE, 2009, 4, e5911.	1.1	18

#	Article	IF	Citations
127	Cirrhosis-like radiological pattern in patients with breast cancer. Clinical and Translational Oncology, 2008, 10, 111-116.	1.2	3
128	Meningeal relapse by follicular lymphoma as a single mass. Clinical and Translational Oncology, 2008, 10, 180-181.	1.2	0
129	Angiogenesis-Related Gene Expression Profile with Independent Prognostic Value in Advanced Ovarian Carcinoma. PLoS ONE, 2008, 3, e4051.	1.1	20
130	Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma. Free Radical Research, 2007, 41, 681-687.	1.5	25
131	High-throughput techniques in breast cancer: A clinical perspective. European Journal of Cancer, 2006, 42, 598-607.	1.3	13
132	Clinical Role of Sm-153 EDTMP in the Treatment of Painful Bone Metastatic Disease. Clinical Nuclear Medicine, 2006, 31, 605-610.	0.7	17
133	Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. Clinical and Translational Oncology, 2005, 7, 239-243.	1.2	3
134	Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study. Journal of Clinical Oncology, 2005, 23, 7278-7285.	0.8	54
135	Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis, 2005, 26, 2095-2104.	1.3	155
136	Implications of Oxidative Stress and Cell Membrane Lipid Peroxidation in Human Cancer (Spain). Cancer Causes and Control, 2004, 15, 707-719.	0.8	138
137	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. Journal of Clinical Oncology, 2004, 22, 3746-3746.	0.8	1
138	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. Journal of Clinical Oncology, 2004, 22, 3746-3746.	0.8	3